EX-16.1 2 mslp_ex161.htm LETTER ON CHANGE IN CERTIFYING ACCOUNTANT Blueprint
 
Exhibit 16.1
 
 
 
 
 
 
October 4, 2018
 
 
Securities and Exchange Commission
Washington, D.C. 20549
 
Commissioners:
 
We have read MusclePharm Corporation’s statements included under Item 4.01 of its Form 8-K filed on October 4, 2018 and we agree with such statements concerning our firm.
 
 
/s/EKS&H LLLP
EKS&H LLLP